About IM Cannabis Corp. IMC (Nasdaq: IMCC) is an international cannabis company that provides premium cannabis products to medical patients in Israel and Germany, two of the largest medical cannabis markets. The Company leverages a transnational ecosystem powered by a unique data-driven approach and a globally sourced product supply chain. With an unwavering commitment to responsible growth and compliance with the strictest regulatory environments, the Company strives to amplify its commercial and brand pow ...

Top Cannabis Stocks to Watch Before November 2025The cannabis industry continues to evolve as investors prepare for potential U.S. federal reform and international market expansion. Despite short-term volatility, global demand for both medical and recreational cannabis is increasing. Analysts project the U.S. cannabis market could exceed $50 billion by 2030, driven by growing legalization efforts and shifting consumer attitudes. However, navigating this emerging sector requires careful attention to fundamen ...

Core Viewpoint - IM Cannabis Corp. has signed a non-binding indicative term sheet to acquire a 60% equity interest in a quantum computing bio data company for up to $54 million, aiming to enhance long-term growth opportunities and shareholder value [1][4]. Company Overview - IM Cannabis Corp. is a leading medical cannabis company operating in Israel and Germany, focusing on premium cannabis products for medical patients in these significant markets [6][7]. - The company aims for sustainable and profitable growth by leveraging a data-driven approach and a globally sourced product supply chain [6]. Proposed Transaction Details - The acquisition involves an aggregate consideration of up to $54 million, which will be paid in cash, IMC shares, and potential earn-out payments based on performance milestones [2]. - The transaction is subject to due diligence, negotiation of definitive agreements, and necessary corporate and regulatory approvals [3]. Strategic Intent - This move follows the company's decision to explore additional business activities to enhance growth opportunities and create further shareholder value [4].

Board Changes - IM Cannabis Corp. announced the resignation of Messrs. Shmulik Arbel and Brian Schinderle from the Board, Audit Committee, and Compensation Committee effective September 15, 2025 [1][2] - Messrs. Asaf Yitzhaik and Eli Zamir have been appointed to the Board and the Audit Committee to fill the vacancies created by the resignations, with Mr. Zamir also joining the Compensation Committee [2] New Board Members - Mr. Yitzhaik has over three decades of experience in retail and real estate, owning ASI Glasses and holding directorships in several publicly traded companies [3] - Mr. Zamir has extensive expertise in finance and capital markets, having served as CEO of an underwriting firm and CFO of a public real estate company, and currently leads M&A and financing activities in the renewable energy sector [4] Leadership Changes - Mr. Oz Adler has been appointed as the new Chairman of the Board, replacing Mr. Oren Shuster, who remains the Chief Executive Officer and a director [5] Strategic Review - The Company is conducting an ongoing strategic review and is exploring the introduction of additional business activities to enhance long-term growth opportunities and create further shareholder value [6] Company Overview - IM Cannabis Corp. is a leading medical cannabis company operating in Israel and Germany, focusing on sustainable and profitable growth in these high-value markets [7] - The Company operates a transnational ecosystem that includes importing and distributing cannabis, retail pharmacies, online platforms, and logistical hubs in Israel, as well as distributing cannabis to pharmacies in Germany through Adjupharm GmbH [8]

Core Points - IM Cannabis Corp. has regained compliance with Nasdaq Listing Rule 5550(b)(1), maintaining stockholders' equity of at least $2,500,000, allowing its common stock to continue trading on the Nasdaq Capital Market [1] Company Overview - IM Cannabis Corp. is an international cannabis company providing premium cannabis products to medical patients in Israel and Germany, two of the largest medical cannabis markets [2] - The company operates a transnational ecosystem powered by a data-driven approach and a globally sourced product supply chain, focusing on responsible growth and regulatory compliance [2] Operations - In Israel, IM Cannabis operates through subsidiaries that import and distribute cannabis to medical patients, utilizing proprietary data and patient insights [3] - The company runs medical cannabis retail pharmacies, online platforms, distribution centers, and logistical hubs in Israel to ensure safe delivery and quality control of its products [3] - In Germany, IM Cannabis operates through Adjupharm GmbH, distributing cannabis to pharmacies for medical cannabis patients [3]

TORONTO and GLIL YAM, Israel, Aug. 13, 2025 /PRNewswire/ -- IM Cannabis Corp. ("IM Cannabis" or the "Company") (NASDAQ: IMCC), a leading medical cannabis company with operations in Israel and Germany, announces that it has agreed with holders (each, a "Holder") of common share purchase warrants ("November 2024 Warrants") issued by the Company as part of its non-brokered private placement offering which closed on November 12, 2024 to: (x) reduce the exercise price of each November 2024 Warrant from C$4.32 to ...

Core Insights - IM Cannabis Corp. reported strong profit and margin growth in Q2 2025 despite a revenue decline due to external challenges such as the ongoing war in Israel and supply chain delays [1][2][12] Financial Highlights - Revenue for Q2 2025 was CAD 12.7 million, a 14% decrease from CAD 14.8 million in Q2 2024, primarily due to a CAD 5.3 million decline in Israel, partially offset by CAD 3.3 million growth in Germany [12] - Gross profit increased by 306% to CAD 3.4 million compared to CAD 0.8 million in Q2 2024, with gross margin rising to 27% from 6% [11][12] - Non-IFRS Adjusted EBITDA showed a profit of CAD 0.1 million in Q2 2025, a 105% improvement from a loss of CAD 2.3 million in Q2 2024 [2][12] - Operating expenses remained stable with a slight increase of 2% to CAD 3.8 million compared to CAD 3.7 million in Q2 2024 [12] Management Commentary - The CEO highlighted the challenges posed by the war and supply chain issues but expressed optimism about the company's profitability and margin growth, indicating a strong long-term strategy [2] - The CFO emphasized disciplined cost management and operational efficiency as key factors in achieving margin expansion despite the revenue decline [2] Company Overview - IM Cannabis Corp. operates in the medical cannabis markets of Israel and Germany, leveraging a data-driven approach and a globally sourced product supply chain [8][9] - The company aims to amplify its commercial and brand power while adhering to strict regulatory environments [8]

Company Overview - IM Cannabis Corp. (NASDAQ: IMCC) is a leading medical cannabis company operating in Israel and Germany, focusing on premium cannabis products for medical patients [2][3] - The company aims for sustainable and profitable growth in its key markets, leveraging a data-driven approach and a globally sourced product supply chain [2] Operational Highlights - The IMC ecosystem in Israel includes subsidiaries that import and distribute cannabis, operate medical cannabis retail pharmacies, and manage online platforms and distribution centers [3] - In Germany, IMC operates through Adjupharm GmbH, distributing cannabis to pharmacies for medical patients [3] Upcoming Financial Reporting - IM Cannabis Corp. will report its operational and financial results for the second quarter of 2025 on August 12, 2025, before the market opens [1]

TORONTO and GLIL YAM, Israel, July 31, 2025 /PRNewswire/ -- IM Cannabis Corp. ("IM Cannabis" or the "Company") (NASDAQ: IMCC), a leading medical cannabis company with operations in Israel and Germany, is pleased to announce that, effective July 30, 2025 (the "Closing Date") it has closed a private placement offering (the "Offering"), through the issuance of 2,050,000 units (each a "Unit") at a price per Unit of C$2.7427 for gross proceeds of C$5,622,522, approximately US$4,100,000, based on an exchange rate ...

Core Viewpoint - IM Cannabis Corp. has filed a shelf registration statement with the SEC, allowing the company to offer and sell up to $50 million of its securities, including common shares, warrants, and units, depending on market conditions and capital needs [1][2]. Company Overview - IM Cannabis Corp. is a leading medical cannabis company operating in Israel and Germany, focusing on providing premium cannabis products to medical patients in these significant markets [5]. - The company aims for sustainable and profitable growth by leveraging a data-driven approach and a globally sourced product supply chain [5]. Operations - In Israel, IM Cannabis operates through subsidiaries that import and distribute cannabis, manage medical cannabis retail pharmacies, and utilize online platforms for distribution [6]. - In Germany, the company distributes cannabis to pharmacies through its subsidiary, Adjupharm GmbH, catering to medical cannabis patients [6]. Shelf Registration Details - The shelf registration allows the company to sell securities on a registered basis, with specific terms and prices to be determined at the time of offering [2][3]. - The registration does not obligate the company to sell any specific amount of securities, as future offerings will depend on market conditions and the company's discretion [3].